| European Case Law Identifier: | ECLI:EP:BA:2001:T022698.20010207 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 07 February 2001 | ||||||||
| Case number: | T 0226/98 | ||||||||
| Application number: | 87306882.9 | ||||||||
| IPC class: | C07D 277/48 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | A | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Morphologically homogenous forms of famotidine and processes for their preparation | ||||||||
| Applicant name: | RICHTER GEDEON VEGYESZETI GYAR R.T. | ||||||||
| Opponent name: | Yamanouchi Pharmaceutical Co., Ltd. | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Main request: clarity (no) - obscurity of delimiting feature | ||||||||
| Catchwords: |
1. In a claim related to a product as such (here: famotidine form "B"), the feature "as a pharmaceutical product" for defining a pharmaceutical standard of purity renders said claim unclear in the absence of a generally accepted quantitative definition for the purported standard of purity. Nor can this expression be considered to be a commonly accepted functional feature as no clear definition can be derived therefrom (see point 7.2 of the reasons). 2. As purity standards are likely to change with time for a number of reasons (e.g. new manufacturing process, new or improved analytical tools, change of criteria for obtaining a marketing authorization), it remains obscure what is considered to be the required product quality when defined by the feature "as a pharmaceutical product" (see point 7.3 of the reasons). |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t980226ex1.html
Date retrieved: 17 May 2021